Mongolian medicine composition for treating viral influenza as well as preparation method and application of Mongolian medicine composition

Abstract

The invention relates to the technical field of Mongolian medicines, in particular to a Mongolian medicine composition for treating viral influenza and a preparation method and application thereof. The Mongolian medicine composition for treating viral influenza is prepared from the following components in parts by mass: 5 to 15 parts of rhaponticum uniflorum, 5 to 10 parts of herba schizonepetae, 5 to 10 parts of liquorice root, 5 to 10 parts of radix angelicae pubescentis, 5 to 10 parts of radix sophorae flavescentis, 5 to 10 parts of radix glehniae, 5 to 10 parts of flos caryophylli and 2.5 to 5 parts of radix et rhizoma rhei. The Mongolian medicine composition for treating the viral influenza has the effects of killing'stickiness', clearing scourge and detoxifying, is definite in curative effect and free of toxic and side effects, can be used for effectively treating the viral influenza, and particularly has good curative effects on fever, headache, running nose, throat discomfort, cough, expectoration, muscular soreness, weakness and other symptoms caused by the influenza.

Description

Technical Field

[0001] The invention relates to the technical field of Mongolian medicines, and in particular to a Mongolian medicine composition for treating viral colds, and a preparation method and application thereof. Background Art

[0002] In Western medicine, viral colds are respiratory diseases caused by viral infection, which are transmitted through air or hand contact, and multiply in the upper respiratory tract after entering the human body, causing the disease. In spring and winter, clustered outbreaks are more common, which can easily lead to large-scale epidemics and widespread spread, so clinical diagnosis and treatment should be taken seriously. For bacterial infectious diseases, they have been well controlled clinically due to the widespread use of antibiotics. However, for the treatment of acute viral upper respiratory tract infections, the treatment effect of Western medicine is not very ideal. The treatment only follows several basic principles such as antiviral, immune regulation and symptom treatment. Moreover, viral antigens often mutate, and the antiviral drugs on the market that have specific inhibitory effects on a specific virus cannot work on the mutated virus, making the existing drugs lose their preventive effect on upper respiratory tract infections caused by new viruses. Modern studies have shown that oseltamivir phosphate capsules can effectively improve clinical symptoms and improve clinical efficacy in the treatment of viral colds, but there are shortcomings such as high prices or certain toxic side effects.

[0003] In Mongolian medicine, viral colds belong to the category of "plague" in Mongolian medicine. When the body's Heyi, Xila, Badagan, etc. show signs of excess or deficiency, and lose balance due to abnormal conditions such as excess or deficiency, symptoms will occur. In Mongolian medicine, this disease is caused by the imbalance of the three roots in the body, also known as the struggle between cold and heat. These symptoms have common characteristics such as seasonality, rapid onset, short course, and the stage from immature fever to mature fever. Clinical manifestations are: in the immature fever period, symptoms generally manifest in the mouth and nose, such as sneezing, nasal congestion, runny nose, etc., and dry cough, dry throat, itchy throat, swallowing pain and burning sensation, chills, fever, fatigue, epistaxis, body aches, headache, temporal and orbital pain, etc. may also occur. During the mature fever stage, symptoms generally include thickened nasal sneezing, yellow phlegm, sore throat when swallowing, sobbing, decreased sense of taste, poor ventilation, hoarseness, etc., and may also include fever reaching a peak, thirst, bitter taste in the mouth, smelly sweat, cough, headache, and increased pain in bones and joints. The general principle of Mongolian medicine for the prevention and treatment of viral colds is to use decoctions to promote maturity in the immature stage to promote its development and maturity.

[0004] Mongolian medicine has a thousand-year heritage, which proves that Mongolian medicine has the advantages of low cost, high efficiency, high safety, etc. in the diagnosis and treatment of viral diseases, and plays an important role. Therefore, in order to make full use of the advantages of Mongolian medicine and improve the service capacity of Mongolian medicine, it is an urgent problem to be solved in the field to provide a Mongolian medicine composition for treating viral colds. Summary of the invention

[0005] In view of the above-mentioned deficiencies in the prior art, the object of the present invention is to provide a Mongolian medicine composition for treating viral colds, and a preparation method and application thereof. The present invention is guided by the theory of Chinese and Mongolian medicine, follows the compatibility principle of Mongolian medicine prescriptions, selects 8 Mongolian medicines that are frequently used in various symptoms of viral colds, and uses dialectical or dialectical and disease differentiation methods to reasonably formulate prescriptions to effectively treat viral colds.

[0006] The technical solution of the present invention is as follows:

[0007] The first aspect of the present invention provides a Mongolian medicine composition for treating viral colds, which comprises the following components, measured by weight: 5-15 parts of ophiopogon japonicus, 5-10 parts of schizonepeta tenuifolia, 5-10 parts of liquorice, 5-10 parts of angelica dahurica, 5-10 parts of sophora flavescens, 5-10 parts of northern adenophora, 5-10 parts of cloves and 2.5-5 parts of rhubarb.

[0008] Optionally, the following components are included, calculated by weight: 10-15 parts of ophiopogon citratus, 5-8 parts of schizonepeta tenuifolia, 5-8 parts of liquorice, 5-8 parts of angelica dahurica, 5-8 parts of sophora flavescens, 5-8 parts of northern adenophora, 5-8 parts of cloves and 2.5-4 parts of rhubarb.

[0009] Optionally, the following components are included, measured by weight: 10 parts of ophiopogon citratus, 5 parts of schizonepeta tenuifolia, 6 parts of liquorice, 7 parts of angelica dahurica, 5 parts of sophora flavescens, 6 parts of northern adenophora, 5 parts of cloves and 4 parts of rhubarb.

[0010] Optionally, the composition is composed of the following components in parts by mass: 10 parts of ophiopogon citratus, 5 parts of schizonepeta tenuifolia, 6 parts of liquorice, 7 parts of angelica dahurica, 5 parts of sophora flavescens, 6 parts of northern adenophora, 5 parts of cloves and 4 parts of rhubarb.

[0011] The second aspect of the present invention provides a method for preparing the Mongolian medicine composition for treating viral colds according to the present invention, comprising the steps of mixing and crushing ophiopogon japonicus, schizonepeta tenuifolia, liquorice, angelica dahurica, sophora flavescens, northern adenophora, cloves and rhubarb in proportion to obtain a target product.

[0012] The third aspect of the present invention provides a use of the Mongolian medicine composition for treating viral colds according to the present invention in the preparation of a medicine for treating viral colds.

[0013] Optionally, the drug is in the form of powder, tea substitute or granules.

[0014] Beneficial effects: The Mongolian medicine composition for treating viral colds of the present invention has the effects of killing "stickiness", clearing away plague and detoxifying, has clear curative effect, has no toxic side effects, can effectively treat viral colds, especially has good curative effect on fever, headache, runny nose, throat discomfort, cough and sputum, muscle aches, physical weakness and other symptoms caused by colds. In addition, it also has the following advantages: 1. The 8 Mongolian medicines selected by the Mongolian medicine composition of the present invention are all used frequently in various symptoms of viral colds, and various symptoms of treating viral colds are also considered, and they conform to the compatibility of "monarch, minister, assistant and messenger", play a synergistic effect, and have good curative effect. 2. The single drug sources of each raw material in the Mongolian medicine composition of the present invention are rich, and belong to the medicinal materials of medicine and food. 3. The Mongolian medicine composition of the present invention can be made into medicines such as powders, tea substitutes or granules, which have the advantages of convenience, safety, shortening the course of disease, and effectiveness. DETAILED DESCRIPTION

[0015] The present invention provides a Mongolian medicine composition for treating viral colds and its preparation method and application. In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0016] According to one embodiment of the present invention, a Mongolian medicine composition for treating viral colds is provided, which includes the following components in parts by mass: 5-15 parts of ophiopogon strychnos, 5-10 parts of schizonepeta, 5-10 parts of licorice, 5-10 parts of angelica dahurica, 5-10 parts of sophora flavescens, 5-10 parts of northern adenophora, 5-10 parts of cloves and 2.5-5 parts of rhubarb.

[0017] The present invention is guided by the theory of Chinese and Mongolian medicine, and uses dialectical or dialectical and disease differentiation to rationally formulate a prescription. The prescription is cool in nature and is a key prescription for treating plague, and has a good therapeutic effect on viral colds. The Mongolian medicine composition of the present invention is rationally formulated with eight medicinal materials, namely, Flos Lophatheri, Herba Schizonepetae, Radix Glycyrrhizae, Radix Angelicae Pubescentis, Radix Sophorae Flavescentis, Radix Adenophorae, Cloves and Radix Rhei, wherein:

[0018] The flower of the loofah, also known as Honggule-Zhuri in Mongolian, is the dried flower of the loofah of Qizhou. The loofah of Qizhou belongs to the genus of ...

[0019] Nepeta is the dried aerial part of Nepeta lobata, a plant of the Labiatae family. It tastes bitter, pungent, astringent, warm, rough, light and dry. It has the effects of killing insects, stopping decay, healing wounds, and removing bad worms. It is used for gastrointestinal parasitic diseases, trichomoniasis, pinworm disease, scabies, psoriasis, etc. For example, the six-flavor Nepeta powder in "Traditional Prescriptions of Mongolian Medicine" is made into powder with Nepeta drooping fruit, Nepeta, syringa, Achillea, Leonurus and Polygonatum, which can treat vaginal trichomoniasis and excessive leucorrhea. The eight-flavor Nepeta powder in "The Most Important Prescriptions" is made into suppositories with Nepeta, syringa, chili, garlic, Zanthoxylum bungeanum, Arisaema, Ligusticum chuanxiong and Artemisia argyi, which can treat anal and vaginal worm diseases, baldness, scabies and other skin worm diseases.

[0020] Licorice is the root and rhizome of the legume plants licorice, licorice inflated fruit, and licorice glabra. It has a sweet taste, is mild in nature, and has a rare, soft, gentle, and light effect. It has the effects of relieving cough, resolving phlegm, clearing heat, moistening the lungs, nourishing, relieving vomiting, quenching thirst, and detoxifying. It is clinically used for tuberculosis, lung heat cough, vomiting blood, thirst, various poisonings, "white vein" disease, sore throat, gastrointestinal "baby day", blood diseases, etc. It is one of the commonly used medicinal materials in Mongolian medicine preparations.

[0021] Angelica dahurica is the root and rhizome of the Umbelliferae plant Angelica sinensis. It has a sweet and spicy taste and is slightly warm in nature. It has the effects of killing armyworms, stopping bleeding, relieving pain, and removing radix syringae. It is used to treat swelling and pain, anthrax, sticky epidemic, diphtheria, various bleedings, leprosy, etc.

[0022] Sophora flavescens is the dried root of the leguminous plant Sophora flavescens. It tastes bitter, is flat, greasy and soft, and has the effects of clearing heat and dampness, killing insects and diuresis. It is used for heat dysentery, blood in stool, jaundice and urine retention, leucorrhea, swelling and itching of the genitals, eczema, wet sores, itching of the skin, scabies and leprosy. The alkaloids in Sophora flavescens have the effects of reducing swelling and diuresis, anti-tumor and anti-pathogens. At the same time, they can also resist arrhythmia and regulate immunity. In addition to treating conventional diseases, it is also used for arrhythmia, heart failure, viral myocarditis, coronary heart disease, etc. This medicine is also one of the commonly used Mongolian medicines. Mongolian medicine mainly uses it to reduce heat, regulate the essence, dry yellow water, and treat superficial rashes. It treats the early stage of plague, wind-heat, measles, rheumatoid arthritis and other diseases.

[0023] Adenophora australis is the dried root of the Umbelliferae plant, which has a sweet and slightly bitter taste, cool nature, light, greasy and soft effect, and has the effects of clearing the lungs and nourishing yin, promoting body fluid and benefiting the stomach, etc. It has significant therapeutic effects in the treatment of lung heat, cough and fever. For example, because it has the effects of removing lung heat and relieving cough, it can be used to treat cough caused by lung heat, cold cough, blood in sputum and other symptoms. It can be combined with medicinal materials such as purple grass antlers that remove blood heat and medicinal materials such as bistort and licorice that have the effect of removing lung heat to form Adenophora australis four-flavor powder.

[0024] Clove is the dried flower bud of the Myrtaceae plant clove. It has a pungent and slightly bitter taste, warm nature, heavy, greasy, solid, soft and dry effect. It has the effects of warming the middle and relieving adverse effects, nourishing the kidney and assisting yang. It has the effects of removing "He Yi", regulating fire, digesting food, appetizing, detoxifying, rashes and relieving sore throat.

[0025] Rhubarb is the dried root and rhizome of Rheum palmatum, Rheum tanguticum or Rheum officinale of the Polygonaceae family. It tastes bitter and sour, is cool in nature, and has a thin, light, floating and rough effect. It has the functions of purging, clearing heat, detoxifying, digesting food and astringing sores. It is used for visceral heat, toxic heat, "xie ri" heat, constipation, amenorrhea, abdominal distension, indigestion, sores, carbuncles, etc.

[0026] The Mongolian medicine composition for treating viral cold provided by the present invention is cold in nature and is a key prescription for treating plague. It is composed of radix scutellariae and radix pubescens with the functions of killing sticky, detoxifying and calming the heat of conflict as the main medicine, schizonepeta with the function of enhancing insecticide and rhubarb with the function of clearing heat and expelling viruses as the ministerial medicine, licorice and northern adenophora with the functions of clearing lung heat, relieving cough and expectoration, nourishing and strengthening the body, and sophora flavescens with the function of making immature heat mature and having the function of sweating as the adjuvant medicine, and cloves with the effect of curing sore throat caused by the symptoms of the cause of disease as the guiding medicine. The prescription has the effects of killing sticky and clearing heat, and each medicinal material complements each other and synergizes, so it has a good curative effect for sticky heat disease and plague diseases. For the Mongolian medicine composition of the present invention, any component is the key that the Mongolian medicine composition of the present invention can effectively and quickly treat viral colds.

[0027] The radix scutellariae in the Mongolian medicine composition of the present invention can be used to treat epidemic fever and toxic heat; liquorice is used for tuberculosis, lung heat, thirst, dry tongue and pharynx, dry and sore throat, nausea and vomiting; sophora flavescens is used to treat the early stage of plague, epidemic fever, and rash poison; angelica dahurica is used to treat sore throat and sticky epidemic; northern adenophora is used for cough, sputum, chest pain, chest tightness, and physical weakness; clove is used for hoarseness; schizonepeta is used for muscle soreness; rhubarb is used for purging toxic heat and visceral heat. The functions of the various component medicinal materials in the whole prescription are clear. These medicinal materials are compounded in a certain proportion, complement each other, and synergize to achieve the effect of treating viral colds from multiple aspects and ways, and can effectively treat fever, headache, runny nose, throat discomfort, cough and sputum, muscle soreness, physical weakness and other symptoms caused by colds.

[0028] The individual herbs in the Mongolian medicine composition of the present invention are frequently used in a large number of Mongolian medicine prescriptions for treating viral colds. Various symptoms of treating viral colds are also taken into consideration when selecting the prescriptions. The composition can prevent and treat viral colds and has the advantages of short treatment time, quick disappearance of symptoms, and the same origin of medicine and food. A preventive dose can be taken when treating initial cold symptoms, and an increased dose can be taken under the guidance of a doctor during treatment. The composition can be used by the elderly, children, and patients with chronic diseases with good effects.

[0029] The Mongolian medicine composition of the present invention adopts 8 medicinal materials which are both medicinal and edible, has a mild formula, has no toxic side effects, can effectively treat diseases, and is especially suitable for children, the elderly and patients with weak constitutions.

[0030] According to a preferred embodiment of the present invention, the following components are included in parts by mass: 10-15 parts of schizonepeta tenuifolia, 5-8 parts of licorice, 5-8 parts of angelica dahurica, 5-8 parts of sophora flavescens, 5-8 parts of northern adenophora, 5-8 parts of cloves and 2.5-4 parts of rhubarb.

[0031] According to a preferred embodiment of the present invention, the following components are included in parts by mass: 10 parts of schizonepeta tenuifolia, 5 parts of licorice, 6 parts of angelica dahurica, 7 parts of angelica pubescens, 5 parts of sophora flavescens, 6 parts of northern adenophora, 5 parts of cloves and 4 parts of rhubarb.

[0032] According to a preferred embodiment of the present invention, the composition is composed of the following components by weight: 10 parts of schizonepeta tenuifolia, 5 parts of schizonepeta tenuifolia, 6 parts of liquorice, 7 parts of angelica dahurica, 5 parts of sophora flavescens, 6 parts of northern adenophora, 5 parts of cloves and 4 parts of rhubarb. Clinical practice has confirmed that this component ratio is the best component ratio and has a good therapeutic effect in the treatment of viral colds.

[0033] In the present invention, rhubarb especially needs to be prepared in a specific ratio and should not be used in excessive amounts, as excessive amounts may cause adverse reactions such as diarrhea. It is necessary to control the amount to the minimum to maximize its effects of purging toxic heat and visceral heat.

[0034] According to one embodiment of the present invention, a method for preparing the Mongolian medicine composition for treating viral colds according to the present invention is provided, comprising the steps of mixing and crushing ophiopogon japonicus, schizonepeta tenuifolia, liquorice, angelica dahurica, sophora flavescens, northern adenophora, cloves and rhubarb in proportion to obtain a target product.

[0035] According to one embodiment of the present invention, there is provided a use of the Mongolian medicine composition for treating viral colds of the present invention in the preparation of a medicine for treating viral colds.

[0036] According to one embodiment of the present invention, the dosage form of the drug is powder, tea substitute or granules.

[0037] Tea substitute refers to the combination of herbs and tea leaves or the processing of herbs (single or compound) into coarse powder, adding water to decoct to extract juice or directly using boiling water to brew, and drinking at any time, in order to achieve a kind of drug dosage form of regulating health, strengthening the body and prolonging life, with the characteristics of convenience, speed and effectiveness. Chinese and Mongolian medicine tea substitutes are guided by the theory of Chinese and Mongolian medicine, and are widely used in the prevention and treatment of various acute and chronic diseases by using dialectics or the combination of dialectics and disease differentiation. The 8 Mongolian medicines contained in the Mongolian medicine composition of the present invention are all medicinal materials with the same origin of medicine and food, so they can be made into tea substitutes, which have the advantages of convenience, safety, speed and effectiveness.

[0038] The present invention will be further described below by means of specific examples.

[0039] Example 1

[0040] This embodiment provides a Mongolian medicine composition for treating viral colds and a preparation method thereof, which are as follows:

[0041] Remove impurities from eight medicinal materials including schizonepeta, licorice, angelica pubescens, sophora flavescens, northern adenophora, cloves and rhubarb and prepare for feeding; take 2 kg of schizonepeta, 1 kg of schizonepeta, 1.2 kg of licorice, 1.4 kg of angelica pubescens, 1 kg of sophora flavescens, 1.2 kg of northern adenophora, 1 kg of cloves and 0.8 kg of rhubarb, mix and grind into 80-100 mesh particle size using a medicine grinder, place in a clean stainless steel barrel, and seal for later use.

[0042] Example 2

[0043] This embodiment provides a Mongolian medicine composition for treating viral colds and a preparation method thereof, which are as follows:

[0044] Remove impurities from eight medicinal materials including ophiopogon foetus, schizonepeta, licorice, angelica pubescens, sophora flavescens, northern adenophora, cloves and rhubarb and prepare for feeding; take 1.5 kg of ophiopogon foetus, 1 kg of schizonepeta, 1 kg of licorice, 1 kg of angelica pubescens, 1 kg of sophora flavescens, 1 kg of northern adenophora, 1 kg of cloves and 0.5 kg of rhubarb, mix and grind into particles of 80-100 mesh using a medicine grinder, place in a clean stainless steel barrel, and seal for later use.

[0045] Example 3

[0046] This embodiment provides a Mongolian medicine composition for treating viral colds and a preparation method thereof, which are as follows:

[0047] Remove impurities from eight medicinal materials including schizonepeta, licorice, angelica pubescens, sophora flavescens, northern adenophora, cloves and rhubarb and prepare for feeding; take 1 kg of schizonepeta, 0.8 kg of schizonepeta, 0.8 kg of licorice, 0.8 kg of angelica pubescens, 0.8 kg of sophora flavescens, 0.8 kg of northern adenophora, 0.8 kg of cloves and 0.4 kg of rhubarb, mix and grind into 80-100 mesh size using a medicine grinder, place in a clean stainless steel barrel, and seal for later use.

[0048] Example 4

[0049] This example provides clinical experiments and statistical analysis results, as follows:

[0050] 1. General Information

[0051] 1.1. Source of cases

[0052] A total of 60 patients (who signed informed consent) who met the diagnostic criteria and exclusion criteria for acute viral upper respiratory tract infection (viral cold) were selected as research subjects and randomly divided into a treatment group and a control group, with 30 patients in each group.

[0053] 1.2 Diagnostic criteria

[0054] 1.2.1. Diagnostic standards of Mongolian medicine (refer to the Diagnosis and Efficacy Standards of Mongolian Medicine):

[0055] (1) Having been to areas where the disease occurs or having contact with such patients;

[0056] (2) high fever, chills, chills, headache, fatigue, joint and skin pain;

[0057] (3) Cough, nasal congestion, sneezing, runny nose, dry and sore throat;

[0058] (4) The disease spreads quickly and can cause illness in many people in a short period of time.

[0059] 1.2.2 Western medicine diagnostic criteria (based on Practical Internal Medicine edited by Chen Haozhu, revised in 2001, 11th edition):

[0060] (1) Acute onset, chills, fever, headache, limb aches and discomfort, and other systemic symptoms, which may be accompanied by nasal congestion, runny nose, and other respiratory tract sputum symptoms;

[0061] (2) Check for throat congestion or swollen and congested tonsils;

[0062] (3) The white blood cell count in venous blood is normal or low, the lymphocyte ratio is increased, and the neutrophil count is not high;

[0063] (4) Exclude infection in other parts of the body.

[0064] 1.3 Case criteria

[0065] 1.3.1. Case inclusion criteria

[0066] (1) Meet the diagnostic criteria;

[0067] (2) within 48 hours after onset of disease;

[0068] (3) Axillary temperature > 37°C;

[0069] (4) Aged 18–65 years at the time of enrollment, regardless of gender;

[0070] (5) Sign the informed consent form.

[0071] 1.3.2 Case exclusion criteria

[0072] (1) Those who are allergic to known ingredients of this medicine;

[0073] (2) Pregnancy and lactation;

[0074] (3) Accompanied by diseases such as purulent tonsillitis;

[0075] (4) Clear bacterial infectious diseases and other causes of fever symptoms;

[0076] (5) Combined with serious underlying diseases such as cardiovascular, cerebrovascular, liver, kidney, and respiratory system diseases;

[0077] (6) Legally or mentally disabled patients.

[0078] 1.3.3. Case dropout criteria

[0079] (1) Patients who experience serious adverse events such as acute cardiovascular and cerebrovascular diseases during medication;

[0080] (2) Patients who develop severe liver, kidney or systemic complications during medication and require other treatments or become pregnant;

[0081] (3) Subjects who violate the clinical trial protocol by taking other drugs or foods, or who are unable to take drugs as prescribed by the doctor;

[0082] (4) Subjects have the right to withdraw from the trial midway and no longer receive medication or testing and thus be lost to follow-up;

[0083] (5) Regardless of the reason, for cases of withdrawal from the trial, the reason for withdrawal should be filled in comprehensively and objectively. If the withdrawal is due to adverse events, the corresponding treatment measures and effects should be recorded, and follow-up records should be kept until the condition stabilizes or the event is properly resolved.

[0084] 2. Research Methods

[0085] 2.1 Treatment methods

[0086] 60 patients (signed informed consent) who met the diagnostic criteria and exclusion criteria for acute viral upper respiratory tract infection were randomly divided into a treatment group and a control group, with 30 patients in each group. The treatment group was given the Mongolian medicine composition prepared in Example 1 (referred to as "Louluhua-8 flavor"), 2 times a day, 3g each time, with warm water; the control group was given Pudilan oral liquid, 3 times a day, 10mL each time, orally. The course of treatment was 7 days, and statistical analysis was performed after the end of the course of treatment.

[0087] 2.2 Observation indicators

[0088] 2.2.1. Efficacy observation indicators

[0089] (1) Observe the changes in symptoms before and after treatment: score the symptoms such as fever, nasal congestion, runny nose, cough, headache, dry throat, sore throat, and swollen tonsils.

[0090] (2) Observe the plasma leukocyte count, C-reactive protein count, interleukin-6 count, etc. before and after treatment.

[0091] 2.2.2 Safety Observation Indicators

[0092] (1) Observe the patient's general vital signs (heart rate, blood pressure, respiration, body temperature) before and after treatment;

[0093] (2) Observe the patient's electrocardiogram, blood routine, urine routine, stool routine, liver function, kidney function and other auxiliary examinations before and after treatment.

[0094] 3. Efficacy and safety evaluation criteria

[0095] 3.1. Criteria for judging the efficacy of Mongolian medicine

[0096] According to the nimodipine method, it is divided into four levels: cure, remarkable effect, effective, and ineffective.

[0097] 3.2 Safety evaluation criteria

[0098] All patient safety-related laboratory tests were within normal ranges.

[0099] 4. Statistical methods

[0100] SPSS software (Statistical Package for the Social Sciences) was used to perform statistical analysis on the collected patient data.

[0101] 4.1 Quantitative Data

[0102] (1) Data were normally distributed and described using t-test and mean ± standard deviation;

[0103] (2) The data did not conform to the normal distribution, so a nonparametric test with two independent samples was used and quartiles were used for description.

[0104] 4.2 Qualitative Data

[0105] Chi-square test was used.

[0106] In the tested data, whether the results are statistically significant is judged based on the P value. P>0.05 is considered to have no statistically significant difference, P<0.05 is considered to have statistically significant difference, and P≤0.01 is considered to have significant statistical significance.

[0107] 5. Research Results

[0108] 5.1 Baseline situation

[0109] 5.1.1 Comparison of gender distribution between the two groups

[0110] A total of 60 patients who met the diagnostic criteria and inclusion criteria were collected, including 10 males, accounting for 16.7%, and 50 females, accounting for 83.3%. Table 1 shows the gender distribution data of the two groups of patients. 2 Denotes chi-square test, P>0.05, the results show that there is no statistically significant difference in gender distribution and they are comparable.

[0111] Table 1

[0112]

[0113] 5.1.2 Comparison of age distribution between the two groups

[0114] A total of 60 patients were included in the two groups, all of whom were aged between 24 and 63 years old. The average age of the treatment group was 45.83±10.94 years old, and the average age of the control group was 41.63±9.97 years old. Tables 2 and 3 show the age distribution data of the two groups of patients. t means t test, X 2 Denotes chi-square test, P>0.05, the results showed that there was no statistically significant difference in the age distribution of patients in the treatment group and the control group, and they were comparable.

[0115] Table 2

[0116]

[0117] Table 3

[0118]

[0119] 5.2. Efficacy evaluation

[0120] 5.2.1 Comparison of symptom scores between the two groups before treatment

[0121] The symptom scores of the two groups of patients were compared before treatment. After normality test, the data did not conform to normal distribution and were described by quartiles. Table 4 is the comparison data of symptom scores between the two groups of patients before treatment. Z represents Z test, P>0.05. The results show that there is no statistically significant difference in symptom scores between the two groups of patients before treatment, and the two groups are comparable.

[0122] Table 4

[0123]

[0124]

[0125] 5.2.2 Comparison of symptom scores between the two groups after treatment

[0126] After treatment, the symptom scores of the two groups of patients were compared. The data were tested for normality and did not conform to normal distribution. Quartiles were used for description. Table 5 shows the comparison data of symptom scores between the two groups of patients after treatment. Z represents Z test. After treatment, the improvement of pharyngeal pain symptoms in the treatment group was significantly better than that in the control group, P≤0.01 (P=0.005).

[0127] Table 5

[0128]

[0129]

[0130] 5.2.3 Comparison of symptom scores before and after treatment between the two groups

[0131] The symptom scores of the two groups of patients before and after treatment were compared. After normality test, the data did not obey normal distribution and were described by quartiles. Table 6 is the comparison data of symptom scores before and after treatment in the two groups of patients. Z represents Z test. The results show that the symptoms of fever, nasal congestion, runny nose, cough, headache, dry throat, sore throat and other symptoms in the treatment group were significantly improved compared with those before treatment, P≤0.01; but there was no statistically significant difference in tonsil enlargement symptoms before and after treatment, P>0.05. The symptoms of nasal congestion, runny nose, headache, dry throat, sore throat and other symptoms in the control group were significantly improved compared with those before treatment, P≤0.01; the fever symptoms of the patients were improved, P<0.05; there was no statistically significant difference in cough and tonsil enlargement symptoms before and after treatment, P>0.05.

[0132] Table 6

[0133]

[0134]

[0135] 5.2.4 Comparison of efficacy between the two groups of patients after treatment

[0136] Table 7 is the comparison data of total effective rate between the two groups. 2 Denotes chi-square test, the results showed that the total effective rate of the treatment group was 80.00%, and the total effective rate of the control group was 76.67%. After comparison between the two groups, there was no statistical difference in the total effective rate between the two groups, P>0.05 (P=0.721).

[0137] Table 7

[0138]

[0139] 5.2.5 Comparison of plasma leukocyte test results before and after treatment between the treatment group and the control group

[0140] Table 8 is the comparison data of plasma leukocyte test results of the two groups of patients, t represents t test, Z represents Z test, and the plasma leukocytes of the two groups of patients before treatment were compared, P>0.05, and the difference was not statistically significant; after treatment, the two groups were compared, and the results showed that the plasma leukocyte level of the control group was lower than that of the treatment group, and the difference was statistically significant, P<0.05 (P=0.045). After treatment, the plasma leukocyte level of the two groups of patients was compared with that before treatment, and there was no statistically significant difference, P>0.05.

[0141] Table 8

[0142]

[0143] 5.2.6 Comparison of C-reactive protein test results before and after treatment between the treatment group and the control group

[0144] The C-reactive protein test results before treatment were compared between the two groups. After normality test, they did not conform to normal distribution, so the non-parametric test Mann-Whitney test was used. Table 9 is the comparison data of C-reactive protein test results between the two groups of patients. Z represents Z test. Before treatment, the C-reactive protein of the two groups of patients was compared, P>0.05, and the results showed that there was no statistically significant difference; after treatment, the two groups were compared, and the results showed that there was no statistically significant difference, P>0.05. After treatment, the intra-group comparison was performed before treatment, and the C-reactive protein level of the two groups of patients was not statistically significant, P>0.05.

[0145] Table 9

[0146]

[0147]

[0148] 5.2.7 Comparison of interleukin-6 test results before and after treatment between the treatment group and the control group

[0149] The interleukin-6 test results before treatment were compared between the two groups. After normality test, it did not conform to normal distribution, so the non-parametric test Mann-Whitney test was used. Table 10 is the comparison data of interleukin-6 test results of the two groups of patients. Z represents Z test. The interleukin-6 of the two groups of patients before treatment was compared, P>0.05, and the results showed that there was no statistically significant difference; after treatment, the two groups were compared, and the results showed that there was no statistically significant difference between the groups, P>0.05. After treatment, the intra-group comparison was performed with that before treatment, and the interleukin-6 levels of the two groups of patients were not statistically significant, P>0.05.

[0150] Table 10

[0151]

[0152] 6. Statistical results of clinical trials

[0153] The above results show that the symptoms of fever, nasal congestion, runny nose, cough, headache, dry throat, sore throat and other symptoms of the treatment group were significantly improved, especially sore throat was significantly better than the control group, and the total effective rate of the treatment group after treatment was 80.00%, which was also higher than the control group. Therefore, "Louluhua-8wei" has a clear effect on patients with viral colds, showing reliable clinical effects, can significantly reduce the inflammatory response of patients, and has fewer side effects and higher safety. It is considered to be an effective choice for the treatment of viral colds.

[0154] Example 5

[0155] This example provides a typical case of treating viral colds with the Mongolian medicine composition prepared in Example 1:

[0156] Typical case 1: Su Moumou, male, born on December 13, 1984. On June 11, 2024, he suffered from a viral cold with symptoms of cough, sputum, sore throat and runny nose. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of cough, sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of sputum improved, the mental state improved, and he recovered after 1 week of oral administration.

[0157] Typical case 2: Si Moumou, female, born on January 2, 1968. On July 5, 2024, she suffered from a viral cold with symptoms of cough, sputum, sore throat and runny nose. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0158] Typical case 3: Liu, male, born on September 2, 1989. On June 10, 2024, he suffered from a viral cold with symptoms of cough, sputum, sore throat, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and he recovered after 1 week of oral administration.

[0159] Typical case 4: Li Moumou, female, born on August 27, 1983. On February 28, 2024, she suffered from a viral cold with symptoms of cough, sore throat, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 4 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 5 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0160] Typical case 5: Wu Moumou, female, born on December 6, 1965. On February 28, 2024, she suffered from a viral cold with symptoms of cough, sputum, sore throat, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 4 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 5 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0161] Typical case 6: Wu Moumou, female, born on July 15, 1995. On March 8, 2024, she suffered from a viral cold with symptoms of body aches, cough, sputum, sore throat, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved. After 5 days of oral administration, the symptoms of body aches, cough, and sputum improved, and the mental state improved. After 1 week of oral administration, the patient recovered.

[0162] Typical case 7: Zhou Moumou, female, born on December 30, 1940. On February 4, 2024, she suffered from a viral cold with symptoms of body aches, cough, sputum, sore throat, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved. After 5 days of oral administration, the symptoms of sore throat, cough, and sputum improved, and the mental state improved. After 1 week of oral administration, the patient recovered.

[0163] Typical case 8: Wu Moumou, female, born on August 7, 1974. On December 29, 2023, she suffered from a viral cold with symptoms of cough, sputum, sore throat, runny nose, and body aches. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved. After 6 days of oral administration, the symptoms of sore throat, runny nose, and mental state improved, and the patient recovered after 1 week of oral administration.

[0164] Typical case 9: A Moumou, female, born on September 3, 1972. On January 9, 2023, she suffered from a viral cold with symptoms of cough, yellow sputum, sore throat, runny nose, ear discomfort, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved. After 6 days of oral administration, the symptoms of sore throat, runny nose, cough, and sputum improved, and the mental state improved. After 1 week of oral administration, the patient recovered.

[0165] Typical case 10: Wu Moumou, female, born on May 17, 1957. On January 10, 2023, she suffered from a viral cold with symptoms of cough, sputum, sore throat, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 5 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0166] Typical case 11: Wu Moumou, female, born on January 27, 1964. On December 14, 2022, she suffered from a viral cold with symptoms of sore throat, cough, sputum, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0167] Typical case 12: Wang Moumou, female, born on December 10, 1958. On October 12, 2022, she suffered from a viral cold with symptoms of sore throat, cough, sputum, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0168] Typical case 13: Gong Moumou, male, born on November 25, 1956. On December 19, 2023, he suffered from a viral cold with symptoms of sore throat, cough, sputum, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and he recovered after 1 week of oral administration.

[0169] Typical case 14: Sheng Moumou, female, born on March 9, 2000. On December 17, 2023, she suffered from a viral cold with symptoms of sore throat, cough, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3 g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0170] Typical case 15: Hu Moumou, female, born on May 23, 1963. On June 5, 2023, she suffered from a viral cold with symptoms of sore throat, cough, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0171] Typical case 16: Si Moumou, male, born on June 14, 1972. On May 29, 2023, he suffered from a viral cold with symptoms of sore throat, cough, runny nose, and bone pain. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3 g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and he recovered after 1 week of oral administration.

[0172] Typical case 17: Wu Moumou, female, born on April 28, 1944. On May 19, 2023, she suffered from a viral cold with symptoms of sore throat, cough, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0173] Typical case 18: Gao Moumou, female, born on February 9, 1953. On May 8, 2023, she suffered from a viral cold with symptoms of sore throat, cough, yellow sputum, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0174] Typical case 19: Luo Moumou, male, born on February 9, 1953. On May 8, 2023, he suffered from a viral cold with symptoms of sore throat, cough, sputum, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and he recovered after 1 week of oral administration.

[0175] Typical case 20: Da Moumou, female, born on April 5, 1939. On April 12, 2023, she suffered from a viral cold with symptoms of sore throat, cough, sputum, runny nose, and general discomfort. The patient took the Mongolian medicine composition prepared in Example 1, 3 times a day, 3g each time, with warm water. After 3 days of oral administration, the symptoms of sore throat and runny nose gradually improved, and after 4 days of oral administration, the symptoms of cough and sputum improved, the mental state improved, and the patient recovered after 1 week of oral administration.

[0176] It should be understood that the application of the present invention is not limited to the above examples. For ordinary technicians in this field, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.

Claims

1. A Mongolian medicine composition for treating viral colds, characterized in that: The invention comprises the following components by weight: 5-15 parts of schizonepeta tenuifolia, 5-10 parts of liquorice, 5-10 parts of angelica dahurica, 5-10 parts of sophora flavescens, 5-10 parts of adenophora adenophora, 5-10 parts of cloves and 2.5-5 parts of rhubarb.

2. The Mongolian medicine composition for treating viral cold according to claim 1, characterized in that: The composition comprises the following components by weight: 10-15 parts of schizonepeta tenuifolia, 5-8 parts of liquorice, 5-8 parts of angelica dahurica, 5-8 parts of sophora flavescens, 5-8 parts of northern adenophora, 5-8 parts of cloves and 2.5-4 parts of rhubarb.

3. The Mongolian medicine composition for treating viral cold according to claim 1, characterized in that: The composition comprises the following components by weight: 10 parts of schizonepeta tenuifolia, 5 parts of schizonepeta tenuifolia, 6 parts of liquorice, 7 parts of angelica dahurica, 5 parts of sophora flavescens, 6 parts of northern adenophora, 5 parts of cloves and 4 parts of rhubarb.

4. The Mongolian medicine composition for treating viral cold according to claim 1, characterized in that: The composition is composed of the following components by weight: 10 parts of schizonepeta tenuifolia, 5 parts of licorice, 6 parts of angelica dahurica, 7 parts of angelica pubescens, 5 parts of sophora flavescens, 6 parts of northern adenophora, 5 parts of cloves and 4 parts of rhubarb.

5. A method for preparing a Mongolian medicine composition for treating viral colds as claimed in any one of claims 1 to 4, characterized in that: The method comprises the steps of mixing and crushing ophiopogon sphagnum, schizonepeta, liquorice, angelica dahurica, sophora flavescens, adenophora australis, clove and rhubarb in proportion to obtain the target product.

6. Use of the Mongolian medicine composition for treating viral colds as described in any one of claims 1 to 4 in the preparation of medicines for treating viral colds.

7. The use according to claim 6, characterized in that: The dosage form of the medicine is powder, tea substitute or granule.

Images